Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00048308 | Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass | PHASE3 | COMPLETED | 3,000 | — | — | Jan 1, 2002 | - | Feb 23, 2017 | 186 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| pexelizumab | DRUG | - |
INCLUSION CRITERIA: The study population will be drawn from patients undergoing CABG or CABG plus valve surgery using a bypass pump. In addition, they must meet all of the following criteria: * be at least 18 years of age; * have one or more of the following risk factors: * diabetes mellitus; * pr...